Please assess the completion status of the following clinical trial:

Trial Title: Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Signed written informed consent according to IGH/EU/GCP and national local laws~* Newly diagnosed untreated ITP adult patients~* Age \> 18 \< 80 years~* Platelet count \<20x109/L~* Platelet count \> 20 x109/L and \<50x109/L plus bleeding with score \> 8 (according to grading scale at paragraph 7.1)~* Baseline Quality of Life evaluation questionnaire filled in Newly diagnosed untreated ITP adult patients~* Age \> 18 \< 80 years~* Platelet count \<20x109/L~* Platelet count \> 20 x109/L and \<50x109/L plus bleeding with score \> 8 (according to grading scale at paragraph 7.1)~* Baseline Quality of Life evaluation questionnaire filled in~Exclusion criteria~* Active malignancy at time of study entry~* Steroids administration (PDN \<1mg/Kg/day) for more than 5 days before randomization~* Concomitant treatment with anti-platelet and or anti-coagulant drugs~* Concomitant severe psychiatric disorders~* Not confirmed diagnosis of ITP for~  * \*Positivity of autoimmunity markers: antinucleus (≥1:80), anti-tireoglobulin, anti-tireoperoxidase, anti-cardiolipin (≥ 40 GPL UmL), anti-b2glycoprotein (≥ 40 IgG U/mL) antibodies, Lupus Anticoagulant (KCT ratio, dRVVT ratios ≥1.5 times the upper normal limit ), direct antiglobulin test (DAT ).~ * Presence of autoimmune hemolytic anemia~ * Presence of connective tissue disease~* Women who are pregnant or breastfeeding~* Cardiovascular diseases requiring treatment~* Severe non-controlled, despite therapy, hypertension and diabetes~* Liver and kidney function impairment (creatinine, ALT, AST \>2 times upper normal limit)~* HCVAb, HIVAb, HBsAg, HBcAb seropositive status~* Chronic liver disease~* Documented viral illness by the positivity of IgM, or vaccination both occurred one month before diagnosis~* Intake of drugs not previously taken within one week before diagnosis~* Bleeding score 15 due to ICH or to GI bleeding (according to grading scale at paragraph 7.1, Tab. 3)~* Active gastric ulcer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ARM A - PDN (Type: EXPERIMENTAL): PDN is administered orally at the daily dose of 1 mg/Kg for 4 consecutive weeks (from day 0 to day 28), then, therapy is tapered within 14 days. The patients considered NOT RESPONDER at day 42 or WHO HAVE LOST THE RESPONSE within the evaluation of final response (see paragraph 8.1), will be crossed to ARM B.
- ARM B - DXM (Type: EXPERIMENTAL): DXM is administered orally at single fixed daily doses of 40 mg for 4 consecutive days, every 14 days, for 3 consecutive courses. If platelet count is £ 20x109/L or bleeding symptoms related to thrombocytopenia are present, lowdose DXM (0.035 mg/Kg/day) between courses is given. The patients (either from ARM A+B or from ARM B) considered NOT RESPONDER at day 46 or who HAVE LOST THE RESPONSE within the evaluation of final response (see paragraph 8.1), will be considered OFF TREATMENT.~For these patients a second line therapy will be considered, according to the medical practice of the Centre (splenectomy or other).

Based on this trial design, predict the completion outcome and termination type (if applicable).